AI Article Synopsis

  • A 34-year-old male with a long-standing epilepsy treated with diphenylhydantoin and phenobarbitone experienced severe status epilepticus that required high doses of these medications intravenously for control.
  • During treatment, he developed acute motor polyneuropathy, especially affecting the legs, along with ongoing cerebellar symptoms.
  • The neuropathy gradually improved over the next year, but the cerebellar symptoms persisted, indicating potential toxic effects of diphenylhydantoin on peripheral nerves, exacerbated by high doses of phenobarbitone.

Article Abstract

In a 34-year-old epileptic male who had been treated for more than ten years with an average of 300 mg diphenylhydantoin and 200-300 mg phenobarbitone daily severe status epilepticus occurred which could only be controlled with high doses of diphenylhydantoin and phenobarbitone intravenously. During this treatment a severe mainly motor polyneuropathy occurred acutely which was more pronounced in the distal parts of the legs, and cerebellar symptoms were noted at the same time. The neuropathy largely regressed during the following year whereas the cerebellar symptoms persisted. There is evidence for direct toxic damage of peripheral nerves due to diphenylhydantoin. Phenobarbitone in high doses inhibits degradation of diphenylhydantoin competively. In this patient it very likely contributed towards the development of sever intoxication leading to neurological defects.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0028-1106417DOI Listing

Publication Analysis

Top Keywords

high doses
8
diphenylhydantoin phenobarbitone
8
cerebellar symptoms
8
diphenylhydantoin
5
[acute polyneuropathy
4
polyneuropathy caused
4
caused diphenylhydantoin
4
diphenylhydantoin intoxication
4
intoxication author's
4
author's transl]
4

Similar Publications

Aflatoxin B1 (AFB1) is a class 1 carcinogen and mycotoxin known to contribute to the development of hepatocellular carcinoma (HCC), growth impairment, altered immune system modulation, and malnutrition. AFB1 is synthesized by Aspergillus flavus and is known to widely contaminate foodstuffs, particularly maize, wheat, and groundnuts. The mechanism in which AFB1 causes genetic mutations has been well studied, however its metabolomic effects remained largely unknown.

View Article and Find Full Text PDF

Several interventional strategies have been implemented in malaria endemic areas where the burden is high, that include among others, intermittent preventive treatment (IPT), a tactic that blocks transmission and can reduce disease morbidity. However, the implementation IPT strategies raises a genuine concern, intervening the development of naturally acquired immunity to malaria which requires continuous contact with parasite antigens. This study investigated whether dihydroartemisinin-piperaquine (DP) or artesunate-amodiaquine (ASAQ) IPT in schoolchildren (IPTsc) impairs IgG reactivity to six malaria antigens.

View Article and Find Full Text PDF

Background: Men who have sex with men (MSM) and transgender women experience high sexually transmitted infection (STI) rates. This study evaluated the feasibility of doxycycline pre-exposure prophylaxis (doxyPrEP) for STI prevention in these key populations.

Methods: Sexually-active MSM and transgender women without HIV with prior syphilis were recruited.

View Article and Find Full Text PDF

Efficacy and safety of risankizumab for the treatment of patients with plaque type psoriasis.

Ital J Dermatol Venerol

January 2025

Department of Dermatology, College of Medicine, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan (ROC) -

Risankizumab (Skyrizi, Abbvie, North Chicago, IL, USA) is a humanized immunoglobulin (Ig) G1 monoclonal antibody targeting the p19 subunit of IL-23, thereby inhibiting IL-23-dependent releasing of proinflammatory cytokines in plaque psoriasis. Risankizumab is licensed is most countries for the treatment of patients with moderate-to-severe plaque psoriasis, and in Japan for generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis. Risankizumab showed higher efficacy and favorable safety profiles in patients with moderate-to-severe plaque psoriasis, compared with adalimumab, secukinumab and ustekinumab in several randomized controlled phase 3 pivotal studies and among real-life data in large retrospective studies.

View Article and Find Full Text PDF

The need for stringent phosphorus removal from domestic wastewater is increasing to mitigate eutrophication, while efficient phosphate reuse is critical due to the global phosphate crisis. Combining aluminum sulfate (ALS) with high molecular weight organic polymers achieved 95-99% removal of particles, turbidity, and phosphates, reducing ALS usage by 40%. We propose mechanisms to explain the enhanced treatment efficiency.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!